Objective: To investigate the potential utility of first trimester screening for Down syndrome using Free beta-hCG, total hCG and PAPP-A.
Materials And Methods: Using estimates from the literature, a simulation study was undertaken to estimate the performance of tests incorporating, Free beta-hCG, total hCG and PAPP-A at gestations of 8-12 weeks. We used sensitivity analysis to assess the effect of departures from the assumed model.
Results: We estimate that detection rates in excess of 75% for a false positive rate (FPR) of 3% can be achieved with first trimester measures of PAPP-A, total hCG and Free beta-hCG at 8 weeks-the addition of total hCG adding 11%. Detection rates of around 90% for a FPR of 3% can be achieved through the inclusion of nuchal translucency (NT) at 12 weeks to these early first trimester biochemical markers. Our analysis indicates that the marginal benefit of adding total hCG diminishes rapidly with gestational age and that there is little benefit from adding total hCG later than 10 weeks of gestation.
Conclusion: The performance of first trimester screening using early combinations of total hCG, Free beta-hCG and PAPP-A should be assessed in further studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pd.1844 | DOI Listing |
Sci Rep
December 2024
Reproductive Medicine Department, Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Currently applicable models for predicting live birth outcomes in patients who received assisted reproductive technology (ART) have methodological or study design limitations that greatly obstruct their dissemination and application. Models suitable for Chinese couples have not yet been identified. We conducted a retrospective study by using a database includes a total of 11,938 couples who underwent in vitro fertilization (IVF) treatment between January 2015 and December 2022 in a medical institution of southwest China Yunnan province.
View Article and Find Full Text PDFBMC Pregnancy Childbirth
December 2024
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, People's Republic of China.
Background: Ectopic pregnancy (EP) accounts for approximately 2% of all pregnancies, with tubal ectopic pregnancies (TEPs) being the most common type. Methotrexate (MTX) is a noninvasive and effective medical management option for TEP, but failure rates range from 10 to 36%, posing challenges in clinical practice. Identifying risk factors for MTX treatment failure is crucial to improve patient outcomes and guide clinical decision-making.
View Article and Find Full Text PDFArch Gynecol Obstet
December 2024
Faculty of Medicine, Department of Gynecology and Obstetrics, Van Yuzuncu Yil University, Van, Turkey.
Purpose: Ectopic pregnancy (EP) constitutes 1-2% of all pregnancies. Methotrexate (MTX) is commonly used in treating EP, but it has some limitations and potential side effects. Clinical studies have shown that letrozole, an aromatase inhibitor, may potentially be used in conjunction with MTX therapy.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
November 2024
Reproductive Health Research Center, Department of Midwifery and Reproductive Health, Al-Zahra Hospital, Guilan University of Medical Sciences, Rasht, Iran.
Considering the relatively high frequency of genetic disorders associated with negative pregnancy outcomes, in this research, adverse pregnancy outcomes in amniocentesis patients were compared between two groups with normal and abnormal maternal serum analytes. This retrospective cohort study was conducted on singleton pregnant women who underwent amniocentesis and had fetuses with normal chromosomes at the perinatology clinic in Rasht. Eligible patients were divided into two groups of 307 people with normal and abnormal maternal serum analytes based on laboratory screening results.
View Article and Find Full Text PDFRev Assoc Med Bras (1992)
December 2024
Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.
Objective: The aim of this study was to evaluate the serum hCG level in the differential diagnosis between non-molar miscarriage and complete hydatidiform mole in<11 weeks gestation.
Methods: This was a retrospective collaborative cohort study. This study included women with gestational age<11 weeks, with ultrasound evidence of failed pregnancy and available serum hCG pre-uterine evacuation, divided into two groups: the non-molar miscarriage group and the complete hydatidiform mole group.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!